To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
-
ATP10B Knockout Cell Line
Cell with homozygous knockout of APT10B.
Estimated Availability: Late 2024
-
ASAH1 Knockout A549 Cell Line
A549 cell with homozygous knockout of ASAH1.
Estimated Availability: Late 2024
-
GALC Knockout A549 Cell Line
A549 cell with homozygous knockout of GALC.
Estimated Availability: Late 2024
-
VPS13C Knockout HeLa Cell Line
HeLa cell with homozygous knockout of VPS13C.
Estimated Availability: Late 2024
-
INPP5F Knockout HeLa Cell Line
HeLa cell with homozygous knockout of INPP5F.
Estimated Availability: Late 2024
-
GCase Activity Probes**
GCase activity probes FQ6 and FQ10. These probes were generated and kindly shared through the MJFF Sponsored Tools Program by David Vocadlo.
Expected Availability: Mid 2024
-
Human GCase Antibody (ICC)*
Monoclonal mouse anti-human GCase antibodies (clones 1/17 and 1/23) for immunocytochemistry applications.
These antibodies were generated by Roche and are kindly made available to academic/non-profit organizations only through the MJFF Sponsored Tools Program.
-
Ubiquitin pS65 Phosphospecific Antibody (Ms ELISA)
Rabbit monoclonal phosphospecific antibody directed against Serine65 of mouse ubiquitin. Suitable for ELISA applications.
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic